3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Brain Neoplasms
6
Glioblastoma
5
Esophageal Neoplasms
3
Childhood Brain Neoplasm
2
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic carcinoma, familial
1
Pancreatic Intraductal Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Neurodegenerative Diseases
1
Neoplasms
1
Lung Carcinoma Metastatic in the Brain
1
Liver Neoplasms
1
Liver Cirrhosis
1
Ischemic Stroke
1
Hypoxia
1
Hemorrhagic Stroke
1
Head and Neck Neoplasms
1
Glioma
1
Cranial Nerve Diseases
1
Colorectal Neoplasms
1
Chondrosarcoma
1
Interventions
Filgrastim
4
Proton Therapy
3
Docetaxel
3
regorafenib
2
Sunitinib
2
Ifosfamide
2
Gemcitabine
2
Carboplatin
2
temsirolimus
1
pegfilgrastim
1
liposomal doxorubicin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
ivosidenib
1
itacitinib
1
etoposide phosphate
1
capivasertib
1
baricitinib
1
apatinib
1
angiotensin I (1-7)
1
abemaciclib
1
Zoledronic Acid
1
Weight-Bearing
1
Trabectedin
1
Topotecan
1
Thiotepa
1
Thalidomide
1
Taxes
1
TQ-B3525
1
Surveys and Questionnaires
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Chondrosarcoma
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts